ADVISORY, Oct. 25, 2013 (GLOBE NEWSWIRE) --
What:
Aerie Pharmaceuticals [AERI], a clinical-stage pharmaceutical company that focuses on the treatment of glaucoma, will visit the NASDAQ MarketSite in Times Square in celebration of its initial public offering (IPO) which occurred on the NASDAQ Stock Market today, October 25.
In honor of the occasion, Vicente Anido, Jr., Ph.D., Chairman and CEO, will ring the Closing Bell.
Where:
NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Friday, October 25, 2013 – 3:45 p.m. to 4:00 p.m. ET
Contact:
Richard Rubino
(908) 470-4320
rrubino@aeriepharma.com
NASDAQ MarketSite:
Christine Barna
(646) 441-5310
Christine.Barna@nasdaqomx.com
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK
Facebook and Twitter:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.
For news tweets, please visit our Twitter page at:
http://twitter.com/nasdaqomx.
Webcast:
A live webcast of the NASDAQ Closing Bell will be available at:
http://www.nasdaq.com/about/marketsitetowervideo.asx.
Photos:
To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About Aerie Pharmaceuticals [AERI]:
Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.
Aerie's lead product candidate, AR-13324, is the first of a new dual-action drug class that was discovered by Aerie scientists. AR-13324 is a once-daily eye drop designed to reduce intraocular pressure in patients with glaucoma or ocular hypertension. Aerie's product candidate PG324 is a fixed combination of dual-action AR-13324 with latanoprost formulated in a single eye drop and is designed to lower intraocular pressure by reducing fluid inflow while also opening both of the eye's fluid drains.
Aerie is located in Bedminster, New Jersey, Research Triangle Park, North Carolina, and Newport Beach, California.
About NASDAQ OMX Group:
The inventor of the electronic exchange, The NASDAQ OMX Group, Inc., fuels economies and provides transformative technologies for the entire lifecycle of a trade - from risk management to trade to surveillance to clearing. In the U.S. and Europe, we own and operate 26 markets, 3 clearinghouses and 5 central securities depositories supporting equities, options, fixed income, derivatives, commodities, futures and structured products. Able to process more than 1 million messages per second at sub-40 microsecond speeds with 99.99% uptime, our technology drives more than 70 marketplaces in 50 developed and emerging countries into the future, powering 1 in 10 of the world's securities transactions. Our award-winning data products and worldwide indexes are the benchmarks in the financial industry. Home to approximately 3,400 listed companies worth $6 trillion in market cap whose innovations shape our world, we give the ideas of tomorrow access to capital today. Welcome to where the world takes a big leap forward, daily. Welcome to the NASDAQ OMX Century. To learn more, visit nasdaqomx.com. Follow us on Facebook (http://www.facebook.com/NASDAQ) and Twitter (http://www.twitter.com/nasdaqomx). (Symbol: NDAQ and member of S&P 500)
-NDAQA-